OCTAVA, NCT05732805: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma |
|
|
| Recruiting | 3 | 270 | RoW | BCD-217, nurulimab+prolgolimab, BCD-100, prolgolimab, Forteca, Placebo | Biocad | Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV, Melanoma Unresectable, Melanoma Metastatic, Melanoma Advanced | 04/24 | 04/25 | | |
JIVAN, NCT05861947: A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies |
|
|
| Recruiting | 1 | 30 | RoW | AUR106 | Aurigene Discovery Technologies Limited | Relapse, Advanced Malignant Neoplasm, Non Small Cell Lung Cancer, Gastric Cancer, Urothelial Carcinoma, Kidney Cancer, Colon Cancer, Esophagus Cancer | 05/25 | 06/25 | | |
